Olema Pharmaceuticals Inc (OLMA) Stock Price, Quote & News

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 651 3316

Website: olema.com

Address:

780 Brannan Street, San Francisco, United States

Vikingsstrade Oct. 3 at 4:23 PM

$RLMD $OLMA $WYFI $MRUS Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

elmono Oct. 2 at 3:00 PM

$OLMA high vol up…low vol down…typical accumulation pattern

0 · Reply

SweepCastApp Oct. 2 at 11:10 AM

$OLMA: Unusual Options Activity Alerted CALL flow observed 221x contracts at Strike price of $12 Exp on 11/21/2025 with Premium of $31K and showing BULLISH Sentiment

0 · Reply

DARKP00L Oct. 1 at 5:33 PM

$OLMA momentum building! Stock attracting attention, could be a mover!

0 · Reply

GottaWearShades Oct. 1 at 5:15 PM

$OLMA yep. hope you held on.

0 · Reply

EvCe Oct. 1 at 3:38 PM

$OLMA congrats to everyone! 🦾 ets keep it up! 🚀

0 · Reply

DarthGoat Sep. 30 at 5:06 PM

$OLMA OOOOUUUTTT +27% All calls in real time.

0 · Reply

highnihilism Sep. 30 at 7:33 AM

$NTSK Netskope: 562 trades, $480K vs $454K avg (1.06x). $394K calls / $86K puts. 98% single-leg. $CNR Core Natural Resources: 221 trades, $421K vs $302K avg (1.40x). $394K calls / $28K puts. 98% single-leg. $OLMA Olema Pharmaceuticals: 534 trades, $392K vs $8K avg (49.3x). $392K calls / $0 puts. 43% single-leg. $STRL Sterling Infrastructure: 102 trades, $484K vs $883K avg (0.55x). $392K calls / $93K puts. 77% single-leg.

0 · Reply

highnihilism Sep. 29 at 4:58 PM

$OLMA Olema Pharma — 1,443 trades, $390K vs $9.6K avg (41x). $390K calls/$523K puts. 57% multi-leg. Heavy biotech options churn.

0 · Reply

Jacoz Sep. 26 at 6:05 PM

$ATYR $OLMA is a better investment at the moment.

0 · Reply

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 7:00 AM EDT - 4 weeks ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

PFE

Aug 20, 2025, 4:30 PM EDT - 6 weeks ago

Olema Oncology to Participate in Upcoming Investor Conferences

Aug 11, 2025, 4:01 PM EDT - 7 weeks ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

May 28, 2025, 7:00 AM EDT - 4 months ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 13, 2025, 4:01 PM EDT - 5 months ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Apr 25, 2025, 1:00 PM EDT - 5 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Apr 8, 2025, 4:25 PM EDT - 6 months ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Mar 25, 2025, 4:31 PM EDT - 6 months ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 7 months ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 7:00 AM EST - 8 months ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Jan 2, 2025, 7:00 AM EST - 9 months ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:46 AM EST - 10 months ago

Top 3 Health Care Stocks That May Explode In Q4

SLN

Dec 10, 2024, 7:00 AM EST - 10 months ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 10 months ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Nov 25, 2024, 5:30 PM EST - 11 months ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 12, 2024, 4:01 PM EST - 11 months ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 28, 2024, 7:03 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 15, 2024, 7:01 AM EDT - 1 year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 1, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 7:03 AM EST - 1 year ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Jan 8, 2024, 8:12 AM EST - 1 year ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Jan 3, 2024, 8:29 AM EST - 1 year ago

Olema Pharmaceuticals: Oral SERD Developer With Interesting Data

Jan 2, 2024, 4:01 PM EST - 1 year ago

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 12:27 PM EST - 1 year ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Nov 28, 2023, 5:10 PM EST - 2 years ago

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Nov 28, 2023, 11:52 AM EST - 2 years ago

Olema Pharmaceuticals: Advancing On Multiple Fronts

Nov 7, 2023, 4:02 PM EST - 2 years ago

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 1, 2023, 4:27 PM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in November

Oct 22, 2023, 2:55 AM EDT - 2 years ago

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

Oct 16, 2023, 7:02 AM EDT - 2 years ago

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

Oct 12, 2023, 7:01 AM EDT - 2 years ago

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Sep 20, 2023, 7:29 AM EDT - 2 years ago

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 3:20 PM EDT - 2 years ago

Olema: Two-Pronged Approach To Treat Breast Cancer Patients

Sep 5, 2023, 7:30 AM EDT - 2 years ago

Olema Oncology Announces Combined Financing for Up to $180 Million

Aug 8, 2023, 4:03 PM EDT - 2 years ago

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference

May 30, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

May 19, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology: Best Contrarian Oncology Play For 2023

May 11, 2023, 8:43 AM EDT - 2 years ago

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

May 9, 2023, 4:01 PM EDT - 2 years ago

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

Vikingsstrade Oct. 3 at 4:23 PM

0 · Reply

elmono Oct. 2 at 3:00 PM

$OLMA high vol up…low vol down…typical accumulation pattern

0 · Reply

SweepCastApp Oct. 2 at 11:10 AM

$OLMA: Unusual Options Activity Alerted CALL flow observed 221x contracts at Strike price of $12 Exp on 11/21/2025 with Premium of $31K and showing BULLISH Sentiment

0 · Reply

DARKP00L Oct. 1 at 5:33 PM

$OLMA momentum building! Stock attracting attention, could be a mover!

0 · Reply

GottaWearShades Oct. 1 at 5:15 PM

$OLMA yep. hope you held on.

0 · Reply

EvCe Oct. 1 at 3:38 PM

$OLMA congrats to everyone! 🦾 ets keep it up! 🚀

0 · Reply

DarthGoat Sep. 30 at 5:06 PM

$OLMA OOOOUUUTTT +27% All calls in real time.

0 · Reply

highnihilism Sep. 30 at 7:33 AM

0 · Reply

highnihilism Sep. 29 at 4:58 PM

$OLMA Olema Pharma — 1,443 trades, $390K vs $9.6K avg (41x). $390K calls/$523K puts. 57% multi-leg. Heavy biotech options churn.

0 · Reply

Jacoz Sep. 26 at 6:05 PM

$ATYR $OLMA is a better investment at the moment.

0 · Reply

Ticker_Licker Sep. 18 at 7:01 PM

$OLMA this goes 10$ once it settles nicely above 8.40$

0 · Reply

Filvul Sep. 18 at 3:11 PM

$OLMA nicee

0 · Reply

highnihilism Sep. 16 at 7:28 PM

IWM: Russell 2000 → $WASH Washington Trust Bancorp $EFC Ellington Financial $TMHC Taylor Morrison $OLMA Olema Pharmaceuticals $RXT Rackspace Technology

0 · Reply

Filvul Sep. 15 at 10:20 PM

$OLMA

0 · Reply

ZacksResearch Sep. 12 at 2:40 PM

$OLMA surges 46.5% so far in September — what's driving the rally? A new collaboration announcement with $PFE for OLMA's palazestrant in a phase Ib/II study for metastatic breast cancer is propelling the stock higher. This marks their second partnership, highlighting strong potential in the oncology space. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2750842/olma-stock-soars-47-in-september-so-far-on-second-pfe-deal?cid=sm-stocktwits-2-2750842-body-12192&ADID=SYND_STOCKTWITS_TWEET_2_2750842_BODY_12192

0 · Reply

ZacksResearch Sep. 12 at 1:40 PM

$OLMA ripping higher — up 47% in September on fresh momentum. The driver? A second Pfizer collaboration tied to its lead breast cancer product candidate, palazestrant. Full breakdown here 👉 https://www.zacks.com/stock/news/2750842/olma-stock-soars-47-in-september-so-far-on-second-pfe-deal?cid=sm-stocktwits-2-2750842-teaser-12191&ADID=SYND_STOCKTWITS_TWEET_2_2750842_TEASER_12191

0 · Reply

Ticker_Licker Sep. 10 at 5:51 PM

$OLMA close above 7.80$ and we’ll see ya at 12$ 🫡 (we’ll see ya there eventually anyway 👀 🤫)

0 · Reply

DarthGoat Sep. 8 at 3:03 PM

$OLMA IIIINNNNNN

1 · Reply

mookiehoedik Sep. 8 at 12:49 PM

$OLMA what's going on in this conference, can we see 10$+ by tonmmorrow at least, yes we can

0 · Reply

EvCe Sep. 8 at 9:56 AM

$OLMA "Moderate Buy and a consensus target price of $24.00” Let’s go above $10 for now

0 · Reply

Aloha98 Sep. 8 at 3:54 AM

$OLMA let s have a nice day bulls 🥳🫶🥰

0 · Reply

StockScanners Sep. 6 at 11:02 AM

$OLMA keep watch if this holds above 7.80

2 · Reply

Market Cap	764.58M
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	787,800
Avg Vol	931,858
Day's Range	N/A - N/A
Shares Out	68.63M
Stochastic %K	91%
Beta	2.08
Analysts	Strong Sell
Price Target	$25.00